PharmacovigilanceOfficial

FDA creates CBER Safety Council to oversee postmarket safety of biologics

🇺🇸 FDA CBER · Thu 19 Nov 2026

The new body replaces CBER's Safety Working Group, sits apart from the product offices and reports directly to the Center Director, effective 19 November 2026.

The US Food and Drug Administration has established the CBER Safety Council (CSC), a governance body within the Center for Biologics Evaluation and Research. It will oversee postmarket safety for CBER-regulated products, including cell and gene therapies, vaccines, and blood and blood products. The council took effect on 19 November 2026 and evolves from CBER's long-standing Safety Working Group.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.